Nutritional and Metabolic Diseases

441 trials 157 recruiting

Filter these 441 trials by phase, country and sponsor.

Open in Search →

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mell… Ended

2024-513539-25-00 Type 2 Diabetes Mellitus 4 2024-11-22
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended

2023-509301-80-00 Severe hypertriglyceridemia (SHTG) 5 2024-11-04
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Hypertriglyceridemia 5 2024-11-04
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended

2023-509300-14-00 Severe hypertriglyceridemia (SHTG) 5 2024-10-31
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) Ended

2024-511450-49-00 Obesity 5 2024-10-22
REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m… Ended

2023-509600-15-00 Type 2 Diabetes 5 2024-10-18
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) Ended

2023-507655-30-00 Obesity 5 2024-09-27
A study to investigate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared w… Ended

2022-500306-17-00 Mucopolysaccharidosis type I, Hurler Syndrome 5 2024-09-20
A Phase 2a Study of Efinopegdutide in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis Ended

2024-510923-20-00 Metabolic Dysfunction-Associated Steatohepatitis 4 2024-09-16
Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Al… Ended

2023-505673-32-00 Hypophosphatasia 5 2024-08-05
DUTCH-WAIST Ended

2022-501392-81-00 Obesity 6 2024-07-25
A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patient… Ended

2023-505316-37-00 Post-Bariatric Hypoglycaemia 4 2024-06-13
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
First-in-human safety study of pancreatic islet transplantation without immune suppression in adult subjects with type 1 diabetes Ended

2023-507988-19-00 Diabetes type I 1 2024-03-08
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study of RZ358 in Patients with Congenital Hyperin… Ended

2023-503240-13-00 Hypoglycemia associated with congenital hyperinsulinism 5 2024-01-30
EVOLVE-MI Ended

2023-509268-26-00 Dyslipidemia 6 2024-01-08
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidit… Ended

2023-504413-80-00 Obesity 5 2023-12-07
A Phase 1/2 Study of BMS-986449 with and without Nivolumab in Participants with Solid Tumors Ended

2023-503484-42-00 Advanced, metastatic, solid malignancy 7 2023-10-19
A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokine… Ended

2023-504215-32-00 Overweight and obesity 9 2023-09-28
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) Ended

2022-502839-19-00 Obesity 5 2023-09-14
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes (REC1TE): a randomized, double-blind, placebo-controll… Ended

2022-502038-23-00 Type 1 diabetes 4 2023-08-25
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
A Safety, Tolerability, and Efficacy Study of VX-264 in Subjects With Type 1 Diabetes Ended

2024-515583-32-00 Type 1 Diabetes Mellitus 7 2023-07-06